Report and Payment. Within [***] after the end of each calendar quarter, commencing with the first calendar quarter during which there is any Net Sales of any Product in any region in the Territory, Licensee shall provide Licensor with a royalty report that contains the following information for the applicable calendar quarter, on a Product-by-Product and region-by-region basis: (i) the amount of gross sales of the Product; (ii) Net Sales of the Product; (iii) a calculation of the royalty payment due on such Net Sales, including the application of any reduction made in accordance with Section 4.3(d), and (iv) the exchange rate for such region. Concurrent with the delivery of the applicable quarterly royalty report, Licensee shall pay Licensor in Dollars all royalties owed with respect to the Net Sales of the Products for such calendar quarter.
Report and Payment. (1) LICENSEE shall report to LICENSOR immediately when MSPA closing has occurred.
Report and Payment. Sanofi will pay royalties pursuant to this Section 6.7 within forty-five (45) days after the end of each Calendar Quarter with respect to applicable Net Sales received in such Calendar Quarter, along with a written report setting forth the Gross Sales, Net Sales and adjustments made pursuant to Sections 6.7.2 and 6.7.3 (if applicable), on a Licensed Product-by-Licensed Product and country-by-country basis, and the total royalty payments payable to Rib-X. The report for the fourth (4th) Calendar Quarter in each Calendar Year will include a list of all countries in which a Licensed Product has been sold in the Territory for the applicable Calendar Year.
Report and Payment. LICENSEE shall provide LICENSOR with a written report as necessary for calculation of the Running Royalties under Section 5.4 of the number of Licensed Technology made, had made, used, imported, offered for sale or sold within the Territory by LICENSEE for each quarterly period ending the last day of March, June, September, and December and make each payment for Licensed Technology on the sixtieth (60th) day from the commencement of each new quarterly period.
Report and Payment. For any Vofatamab Transaction Revenue Sharing due under this Section 1.06, and subject to Section 1.06(c) with respect to the timing of Vofatamab Transaction Revenue Sharing payments under certain Vofatamab Transactions, Purchaser shall make such Vofatamab Transaction Revenue Sharing within [***] days following the receipt of the applicable Vofatamab Transaction Revenue. All payments shall be accompanied by a report that includes a calculation of all payments payable to Seller and/or, if after dissolution of Seller, the Seller Representative’s designee, under this Section 1.06.
Report and Payment. Biodexa shall, within thirty (30) days following the end of each Calendar Quarter, commencing with the First Commercial Sale of a Licensed Product in the Territory, provide to Melior a written report showing the total Net Sales of Licensed Products in the Territory for that Calendar Quarter stated in U.S. Dollars and the royalties due thereon. Such report shall include the gross amount invoiced by Biodexa or any of its Affiliates or Sublicensees to any third party for the sale to such third party of Licensed Products; the type and amount of all deductions and offsets allocated with respect to such sale of Licensed Products; the calculation of Net Sales, including the applicable royalty rate; the calculation of sublicensing revenue, including the type and amount of all Sublicensee payments; the exchange rate used for calculating any royalties and sublicensing revenue; and such other particulars as are reasonably necessary for an accurate accounting of the payments due pursuant to this Agreement.
Report and Payment. Within [***] days after each calendar quarter, commencing with the calendar quarter during which any Net Sales of the Product are made anywhere in the Territory, Licensee shall provide Licensor with a report that contains the following information for the applicable calendar quarter, on a country-by-country basis: (i) the amount of gross sales of the Product, (ii) an itemized calculation of Net Sales in the Territory showing separately each type of deduction provided for in the definition of “Net Sales,” (iii) a calculation of the royalty payment due on such sales, including the application of any reduction made in accordance with Section 4.5(c), (iv) the exchange rate for such country; and (v) the aggregate annual Net Sales and whether any commercial milestone has been achieved. Concurrent with the delivery of the applicable quarterly report, Licensee shall pay Licensor in Dollars all royalties owed with respect to Net Sales for such calendar quarter.
Report and Payment. Within [ ] ([ ]) [ ] after the end of each Calendar Quarter during which Net Sales occur on which Arctic Vision is required to pay to Eyenovia royalties under this Section 5.5, Arctic Vision shall provide Eyenovia with a royalty report that contains the following information for the applicable Calendar Quarter, on a Product-by-Product and Jurisdiction-by-Jurisdiction basis: (i) the amount of gross sales of the Product, (ii) a calculation of Net Sales of the Product (include a reasonably detailed accounting of any deductions from gross sales), (iii) a calculation of the royalty payment due on such Net Sales, including the application of any reduction made in accordance with Section 5.5(c) or 5.6, (iv) the exchange rate for such Jurisdiction, and (v) the aggregate annual Net Sales of each Product. Concurrent with the delivery of the applicable quarterly royalty report, Arctic Vision shall pay Eyenovia in Dollars the royalties owed with respect to Net Sales for such Calendar Quarter.
Report and Payment. Within thirty (30) days after the end of each Calendar Quarter, commencing with the First Commercial Sale of an ATRASENTAN Licensed Product in the Territory, Licensee shall provide Licensor with a royalty report that contains the following information for the applicable calendar quarter, on an ATRASENTAN Licensed Product-by-ATRASENTAN Licensed Product and jurisdiction-by-jurisdiction basis: (i) the amount of gross sales of the ATRASENTAN Licensed Product, (ii) a calculation of Net Sales of the ATRASENTAN Licensed Product, (iii) a calculation of the royalty payment due on such Net Sales [*** ] (iv) the exchange rate for such jurisdiction, and (v) the amount of Taxes, if any, withheld to comply with applicable Laws. Licensor shall determine the royalty rates and royalty amounts applicable to Licensee’s Net Sales in the Territory [***] within five (5) days of receiving Licensee’s royalty report hereunder, and in any event no later than ten (10) days prior to the date of Licensor’s invoice for payment of royalties for the applicable calendar quarter. Licensee shall pay Licensor in Dollars the royalties owed (as may be adjusted pursuant to Section 5.3) with respect to Net Sales for such Calendar Quarter within thirty (30) days after the receipt of the invoice issued by Licensor for such calendar quarter.
Report and Payment. (1) JVC shall act as the licensing agent to cooperate with DISKXPRESS to collect all licensing income with respect to the Patents and shall receive fees for its services as agent, all as provided in this Article 4.
